Trial Profile
A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 08 Nov 2023 Status changed from active, no longer recruiting to completed.
- 20 Jul 2021 Planned End Date changed from 31 Mar 2023 to 1 Nov 2023.
- 20 Jul 2021 Planned primary completion date changed from 31 Mar 2023 to 1 Nov 2023.